BCM
VOR icon

Bourgeon Capital Management’s Vor Biopharma VOR Stock Holding History

Bourgeon Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,473
Closed -$69.8K – 117
2024
Q1 		$69.8K Hold
1,473
– – 0.01% 112
2023
Q4 		$66.3K Buy
1,473
+125
+9% +$5.16K 0.01% 137
2023
Q3 		$57.1K Buy
1,348
+225
+20% +$12.2K 0.01% 137
2023
Q2 		$69.4K Buy
1,123
+200
+22% +$18.3K 0.02% 137
2023
Q1 		$99.3K Buy
923
+363
+65% +$40.2K 0.02% 117
2022
Q4 		$74.5K Buy
560
+25
+5% +$2.47K 0.02% 134
2022
Q3 		$43K Buy
535
+150
+39% +$14.7K 0.01% 142
2022
Q2 		$38K Hold
385
– – 0.01% 149
2022
Q1 		$47K Sell
385
-145
-27% -$24.7K 0.01% 148
2021
Q4 		$123K Buy
530
+227
+75% +$65.4K 0.03% 117
2021
Q3 		$95K Buy
303
+213
+237% +$63.3K 0.02% 129
2021
Q2 		$34K Buy
+90
New +$44.4K 0.01% 179

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bourgeon Capital Management's VOR Position: Q2 2024 in Review

Bourgeon Capital Management sold out of Vor Biopharma (VOR) in Q2 2024, closing a stake of 1,473 shares — an estimated $69.8K sold.

Bourgeon Capital Management first reported a position in VOR in Q2 2021 and held it in 12 quarters. The position peaked at $123K in Q4 2021. 71 funds tracked by Wall St. Rank hold VOR as of Q2 2024.

  • Bourgeon Capital Management reported no remaining Vor Biopharma position as of Q2 2024 after selling out during the quarter.
  • Bourgeon Capital Management sold 1,473 Vor Biopharma shares in Q2 2024, an estimated $69.8K.
  • Bourgeon Capital Management first reported a position in Vor Biopharma in Q2 2021 and held it in 12 quarters.
  • Bourgeon Capital Management's Vor Biopharma position peaked at $123K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2024.

Based on Bourgeon Capital Management's 13F filing for Q2 2024, filed 11 Jul 2024.